317 related articles for article (PubMed ID: 18585457)
1. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.
Taylor RP; Lindorfer MA
Curr Opin Immunol; 2008 Aug; 20(4):444-9. PubMed ID: 18585457
[TBL] [Abstract][Full Text] [Related]
2. Novel CD20 monoclonal antibodies for lymphoma therapy.
Cang S; Mukhi N; Wang K; Liu D
J Hematol Oncol; 2012 Oct; 5():64. PubMed ID: 23057966
[TBL] [Abstract][Full Text] [Related]
3. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
Kohrt HE; Thielens A; Marabelle A; Sagiv-Barfi I; Sola C; Chanuc F; Fuseri N; Bonnafous C; Czerwinski D; Rajapaksa A; Waller E; Ugolini S; Vivier E; Romagné F; Levy R; Bléry M; André P
Blood; 2014 Jan; 123(5):678-86. PubMed ID: 24326534
[TBL] [Abstract][Full Text] [Related]
4. [CD20 antibody for the treatment of systemic autoimmune diseases].
Tanaka Y
Nihon Rinsho; 2005 May; 63 Suppl 5():728-33. PubMed ID: 15954437
[No Abstract] [Full Text] [Related]
5. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
[TBL] [Abstract][Full Text] [Related]
6. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
Shaw T; Quan J; Totoritis MC
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii55-9. PubMed ID: 14532151
[No Abstract] [Full Text] [Related]
7. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.
Winiarska M; Glodkowska-Mrowka E; Bil J; Golab J
Front Biosci (Landmark Ed); 2011 Jan; 16(1):277-306. PubMed ID: 21196171
[TBL] [Abstract][Full Text] [Related]
8. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
9. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
Tanaka Y
Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
[TBL] [Abstract][Full Text] [Related]
10. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
Beum PV; Lindorfer MA; Taylor RP
J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
[TBL] [Abstract][Full Text] [Related]
11. [Molecular mechanisms of B lymphocyte depletion by CD20 immunotherapy].
Hamaguchi Y
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Feb; 32(1):29-34. PubMed ID: 19252375
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
[TBL] [Abstract][Full Text] [Related]
13. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.
Kennedy AD; Beum PV; Solga MD; DiLillo DJ; Lindorfer MA; Hess CE; Densmore JJ; Williams ME; Taylor RP
J Immunol; 2004 Mar; 172(5):3280-8. PubMed ID: 14978136
[TBL] [Abstract][Full Text] [Related]
14. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
Beum PV; Mack DA; Pawluczkowycz AW; Lindorfer MA; Taylor RP
J Immunol; 2008 Dec; 181(11):8120-32. PubMed ID: 19018005
[TBL] [Abstract][Full Text] [Related]
15. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
16. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
Czuczman MS; Gregory SA
Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.
Bowles JA; Wang SY; Link BK; Allan B; Beuerlein G; Campbell MA; Marquis D; Ondek B; Wooldridge JE; Smith BJ; Breitmeyer JB; Weiner GJ
Blood; 2006 Oct; 108(8):2648-54. PubMed ID: 16825493
[TBL] [Abstract][Full Text] [Related]
18. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
19. [Advances in the research of anti-CD20 therapeutic monoclonal antibodies].
Deng CL; Zou J; Song HF
Yao Xue Xue Bao; 2013 Oct; 48(10):1515-20. PubMed ID: 24417077
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD20 monoclonal antibodies: beyond B-cells.
Avivi I; Stroopinsky D; Katz T
Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
